应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
OGN Organon & Co
盘前交易 12-05 07:36:59 EST
7.14
-0.13
-1.79%
盘前
7.21
+0.07
+0.98%
05:06 EST
最高
7.32
最低
7.09
成交量
317.83万
今开
7.28
昨收
7.27
日振幅
3.16%
总市值
18.56亿
流通市值
18.47亿
总股本
2.60亿
成交额
2,283万
换手率
1.23%
流通股本
2.59亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Henlius与Organon宣布美国FDA批准Poherdy®(Pertuzumab-Dpzb),首个在美国获批的Perjeta(Pertuzumab)生物类似药
美股速递 · 11-17
Henlius与Organon宣布美国FDA批准Poherdy®(Pertuzumab-Dpzb),首个在美国获批的Perjeta(Pertuzumab)生物类似药
Organon & Co.2025财年第三财季实现净利润1.60亿美元,同比减少55.43%
市场透视 · 11-17
Organon & Co.2025财年第三财季实现净利润1.60亿美元,同比减少55.43%
异动解读 | 摩根大通下调目标价,Organon & Co盘中大跌5.06%
异动解读 · 11-11
异动解读 | 摩根大通下调目标价,Organon & Co盘中大跌5.06%
Organon 股价在盘前上涨 1.8%,因公司宣布与 Laborie 达成协议,将其 Jada 系统以高达 4.65 亿美元出售
美股速递 · 11-07
Organon 股价在盘前上涨 1.8%,因公司宣布与 Laborie 达成协议,将其 Jada 系统以高达 4.65 亿美元出售
Organon(OGN.US)因内部控制问题重挫,再遭Piper Sandler大砍目标价至5美元
智通财经 · 10-28
Organon(OGN.US)因内部控制问题重挫,再遭Piper Sandler大砍目标价至5美元
Organon股价创历史新低,首席执行官Kevin Ali因避孕植入物销售调查辞职,股价最终下跌21%
美股速递 · 10-27
Organon股价创历史新低,首席执行官Kevin Ali因避孕植入物销售调查辞职,股价最终下跌21%
Organon股价盘前下跌17.5%,因首席执行官Kevin Ali因避孕植入物销售调查辞职
美股速递 · 10-27
Organon股价盘前下跌17.5%,因首席执行官Kevin Ali因避孕植入物销售调查辞职
Organon & Co:不当的Nexplanon销售行为使公司能够达到指导目标和某些外部收入预期
美股速递 · 10-27
Organon & Co:不当的Nexplanon销售行为使公司能够达到指导目标和某些外部收入预期
Organon & Co: 目前发现不需要对以往财务报表进行重述或修订
美股速递 · 10-27
Organon & Co: 目前发现不需要对以往财务报表进行重述或修订
Organon & Co:启动寻找常任首席执行官的工作,包括内部和外部候选人
美股速递 · 10-27
Organon & Co:启动寻找常任首席执行官的工作,包括内部和外部候选人
Organon:调查发现Nexplanon销售额在截至2022年12月31日或2024年12月31日的年度中占公司合并收入的比例不足1%
美股速递 · 10-27
Organon:调查发现Nexplanon销售额在截至2022年12月31日或2024年12月31日的年度中占公司合并收入的比例不足1%
Organon \u0026 Co:采取补救措施以改善财务控制并解决任何重大缺陷
美股速递 · 10-27
Organon \u0026 Co:采取补救措施以改善财务控制并解决任何重大缺陷
Organon: 调查发现美国部分批发商被要求在2022年第四季度末、2024年第三和第四季度、2025年第一、第二和第三季度购买超过需求的Nexplanon
美股速递 · 10-27
Organon: 调查发现美国部分批发商被要求在2022年第四季度末、2024年第三和第四季度、2025年第一、第二和第三季度购买超过需求的Nexplanon
Organon任命公司高管Joseph Morrissey为临时首席执行官,董事会主席Carrie Cox为执行主席;公布审计委员会调查结果
美股速递 · 10-27
Organon任命公司高管Joseph Morrissey为临时首席执行官,董事会主席Carrie Cox为执行主席;公布审计委员会调查结果
欧盟委员会批准复宏汉霖和Organon公司的Bildyos®(地诺单抗)和Bilprevda®(地诺单抗)生物类似药,分别为Prolia(地诺单抗)和Xgeva(地诺单抗)的生物类似药
美股速递 · 09-19
欧盟委员会批准复宏汉霖和Organon公司的Bildyos®(地诺单抗)和Bilprevda®(地诺单抗)生物类似药,分别为Prolia(地诺单抗)和Xgeva(地诺单抗)的生物类似药
Organon & Co.盘中异动 股价大涨5.02%报10.88美元
市场透视 · 09-18
Organon & Co.盘中异动 股价大涨5.02%报10.88美元
首个“中国籍”地舒单抗在美获批上市!复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场
智通财经 · 09-02
首个“中国籍”地舒单抗在美获批上市!复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场
美国FDA批准复宏汉霖和Organon & Co的Bildyos®(德诺单抗-Nxxp)和Bilprevda®(德诺单抗-Nxxp),分别为Prolia(德诺单抗)和Xgeva(德诺单抗)的生物类似药
美股速递 · 09-02
美国FDA批准复宏汉霖和Organon & Co的Bildyos®(德诺单抗-Nxxp)和Bilprevda®(德诺单抗-Nxxp),分别为Prolia(德诺单抗)和Xgeva(德诺单抗)的生物类似药
Organon & Co.2025财年第二财季实现净利润1.45亿美元,同比减少25.64%
市场透视 · 08-11
Organon & Co.2025财年第二财季实现净利润1.45亿美元,同比减少25.64%
Organon & Co.盘中异动 下午盘急速上涨5.05%
市场透视 · 08-08
Organon & Co.盘中异动 下午盘急速上涨5.05%
公司概况
公司名称:
Organon & Co
所属市场:
NYSE
上市日期:
--
主营业务:
Organon & Co.是一家特拉华州公司,成立于2020年3月11日。Organon是一家基于科学的全球制药公司,通过一系列针对女性健康,生物仿制药和知名品牌的处方疗法,开发并提供创新的健康解决方案。他们的使命是成为世界领先的女性保健公司,每天为每个女性提供更好,更健康的服务。他们计划利用自身在生殖健康方面的优势,建立一系列健康解决方案,为从青春期到更年期及以后的妇女提供服务。
发行价格:
--
{"stockData":{"symbol":"OGN","market":"US","secType":"STK","nameCN":"Organon & Co","latestPrice":7.14,"timestamp":1764882000000,"preClose":7.27,"halted":0,"volume":3178283,"hourTrading":{"tag":"盘前","latestPrice":7.21,"preClose":7.14,"latestTime":"05:06 EST","volume":10,"amount":72.1,"timestamp":1764929217732},"delay":0,"floatShares":258733290,"shares":259982912,"eps":1.911771,"marketStatus":"盘前交易","change":-0.13,"latestTime":"12-05 07:36:59 EST","open":7.28,"high":7.32,"low":7.09,"amount":22827868.268199,"amplitude":0.031637,"askPrice":7.22,"askSize":100,"bidPrice":7.18,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.911771,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1764945000000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":7.14,"dividendRate":0.047619,"preHourTrading":{"tag":"盘前","latestPrice":7.21,"preClose":7.14,"latestTime":"05:06 EST","volume":10,"amount":72.1,"timestamp":1764929217732},"postHourTrading":{"tag":"盘后","latestPrice":7.2,"preClose":7.14,"latestTime":"19:36 EST","volume":77497,"amount":553508.3104,"timestamp":1764894995663},"volumeRatio":0.8091835751862508,"impliedVol":0.6367,"impliedVolPercentile":0.5422},"requestUrl":"/m/hq/s/OGN/wiki","defaultTab":"wiki","newsList":[{"id":"1155289447","title":"Henlius与Organon宣布美国FDA批准Poherdy®(Pertuzumab-Dpzb),首个在美国获批的Perjeta(Pertuzumab)生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1155289447","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155289447?lang=zh_cn&edition=full","pubTime":"2025-11-17 18:32","pubTimestamp":1763375530,"startTime":"0","endTime":"0","summary":"Henlius与Organon宣布,美国FDA已批准Poherdy®(Pertuzumab-Dpzb),这是首个在美国获批的Perjeta(Pertuzumab)生物类似药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN","BK4559","BK4585","LU2065170008.USD","BK4588","LU2065171402.SGD","BK4007","LU2065169927.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2584399624","title":"Organon & Co.2025财年第三财季实现净利润1.60亿美元,同比减少55.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584399624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584399624?lang=zh_cn&edition=full","pubTime":"2025-11-17 00:01","pubTimestamp":1763308866,"startTime":"0","endTime":"0","summary":"11月17日,Organon & Co.公布财报,公告显示公司2025财年第三财季净利润为1.60亿美元,同比减少55.43%;其中营业收入为16.02亿美元,同比增加1.26%,每股基本收益为0.62美元。从资产负债表来看,Organon & Co.总负债126.46亿美元,其中短期债务45.00百万美元,资产负债比为1.08,流动比率为1.76。机构评级:截至2025年11月17日,当前有6家机构对Organon & Co.目标价做出预测,其中目标均价为9.67美元,其中最低目标价为5.00美元,最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000126a6fd6c9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000126a6fd6c9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGN"],"gpt_icon":0},{"id":"1181983631","title":"异动解读 | 摩根大通下调目标价,Organon & Co盘中大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181983631","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181983631?lang=zh_cn&edition=full","pubTime":"2025-11-11 23:34","pubTimestamp":1762875267,"startTime":"0","endTime":"0","summary":"周二盘中,Organon & Co股价出现大幅下跌,跌幅达5.06%,引发投资者关注。造成股价下跌的主要原因可能是华尔街知名投行摩根大通对该公司股票的最新评估。根据最新报告,摩根大通分析师将Organon & Co的目标价从14美元下调至12美元。投资者可能会根据这一新的分析调整其投资策略,导致抛售压力增加。Organon & Co今日的股价大跌似乎直接反映了市场对这一分析师评级变化的反应。投资者应密切关注公司未来的财务表现和市场动态,以评估这一下跌是否会持续。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["OGN"],"gpt_icon":0},{"id":"1186695436","title":"Organon 股价在盘前上涨 1.8%,因公司宣布与 Laborie 达成协议,将其 Jada 系统以高达 4.65 亿美元出售","url":"https://stock-news.laohu8.com/highlight/detail?id=1186695436","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186695436?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518985,"startTime":"0","endTime":"0","summary":"Organon 股价在盘前上涨 1.8%,因公司宣布与 Laborie 达成协议,将其 Jada 系统以高达 4.65 亿美元出售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD","BK4585","OGN","LU2065171402.SGD","BK4559","BK4588","BK4007"],"gpt_icon":0},{"id":"2578981199","title":"Organon(OGN.US)因内部控制问题重挫,再遭Piper Sandler大砍目标价至5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578981199","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578981199?lang=zh_cn&edition=full","pubTime":"2025-10-28 14:45","pubTimestamp":1761633937,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,Piper Sandler将Organon的评级从“增持”下调至“减持”,并将目标股价从 18 美元下调至 5 美元。此次行动是在审计委员会对公司进行调查之后采取的,该调查揭露了公司在其避孕产品“Nexplanon”方面存在重大内部控制缺陷,导致 2022 年、2024 年和 2025 年的财务报表出现错误陈述。周一,该公司股价收跌约23%。此次评级下调表明,Piper Sandler认为Organon的复苏之路漫长,这主要是由于需要恢复内部控制和投资者信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Organon(OGN.US)因内部控制问题重挫,再遭Piper Sandler大砍目标价至5美元","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["OGN"],"gpt_icon":0},{"id":"1143846624","title":"Organon股价创历史新低,首席执行官Kevin Ali因避孕植入物销售调查辞职,股价最终下跌21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143846624","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143846624?lang=zh_cn&edition=full","pubTime":"2025-10-27 21:39","pubTimestamp":1761572352,"startTime":"0","endTime":"0","summary":"Organon股价创历史新低,首席执行官Kevin Ali因避孕植入物销售调查辞职,股价最终下跌21%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4585","LU2065170008.USD","BK4007","BK4559","LU2065171311.SGD","LU2065169927.USD","BK4588","OGN"],"gpt_icon":0},{"id":"1136210617","title":"Organon股价盘前下跌17.5%,因首席执行官Kevin Ali因避孕植入物销售调查辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=1136210617","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136210617?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:09","pubTimestamp":1761566953,"startTime":"0","endTime":"0","summary":"Organon股价盘前下跌17.5%,因首席执行官Kevin Ali因避孕植入物销售调查辞职。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN","BK4559","BK4585","LU2065170008.USD","BK4588","LU2065171402.SGD","BK4007","LU2065169927.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"1156321012","title":"Organon & Co:不当的Nexplanon销售行为使公司能够达到指导目标和某些外部收入预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1156321012","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156321012?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:40","pubTimestamp":1761565215,"startTime":"0","endTime":"0","summary":"Organon & Co:不当的Nexplanon销售行为使公司能够达到指导目标和某些外部收入预期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4559","LU2065170008.USD","LU2065169927.USD","BK4007","OGN","LU2065171402.SGD","LU2065171311.SGD"],"gpt_icon":0},{"id":"1169579286","title":"Organon & Co: 目前发现不需要对以往财务报表进行重述或修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1169579286","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169579286?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564864,"startTime":"0","endTime":"0","summary":"Organon & Co: 目前发现不需要对以往财务报表进行重述或修订","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD","OGN","BK4585","BK4559","BK4588"],"gpt_icon":0},{"id":"1188215591","title":"Organon & Co:启动寻找常任首席执行官的工作,包括内部和外部候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=1188215591","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188215591?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564856,"startTime":"0","endTime":"0","summary":"Organon & Co:启动寻找常任首席执行官的工作,包括内部和外部候选人","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","OGN","BK4588","LU2065171402.SGD","LU2065170008.USD","BK4007","BK4559","BK4585","LU2065171311.SGD"],"gpt_icon":0},{"id":"1118094156","title":"Organon:调查发现Nexplanon销售额在截至2022年12月31日或2024年12月31日的年度中占公司合并收入的比例不足1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118094156","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118094156?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564856,"startTime":"0","endTime":"0","summary":"Organon:调查发现Nexplanon销售额在截至2022年12月31日或2024年12月31日的年度中占公司合并收入的比例不足1%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OGN","LU2065170008.USD","BK4585","LU2065171402.SGD","LU2065169927.USD","BK4588","BK4559","LU2065171311.SGD"],"gpt_icon":0},{"id":"1169861830","title":"Organon \\u0026 Co:采取补救措施以改善财务控制并解决任何重大缺陷","url":"https://stock-news.laohu8.com/highlight/detail?id=1169861830","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169861830?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564854,"startTime":"0","endTime":"0","summary":"Organon \\u0026 Co:采取补救措施以改善财务控制并解决任何重大缺陷","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","OGN","BK4588","BK4585","BK4559","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","BK4007"],"gpt_icon":0},{"id":"1158170986","title":"Organon: 调查发现美国部分批发商被要求在2022年第四季度末、2024年第三和第四季度、2025年第一、第二和第三季度购买超过需求的Nexplanon","url":"https://stock-news.laohu8.com/highlight/detail?id=1158170986","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158170986?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:33","pubTimestamp":1761564790,"startTime":"0","endTime":"0","summary":"Organon: 调查发现美国部分批发商被要求在2022年第四季度末、2024年第三和第四季度、2025年第一、第二和第三季度购买超过需求的Nexplanon","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4588","LU2065170008.USD","LU2065171311.SGD","OGN","LU2065169927.USD","BK4585","BK4559","BK4007"],"gpt_icon":0},{"id":"1135379781","title":"Organon任命公司高管Joseph Morrissey为临时首席执行官,董事会主席Carrie Cox为执行主席;公布审计委员会调查结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1135379781","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135379781?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:31","pubTimestamp":1761564702,"startTime":"0","endTime":"0","summary":"Organon任命公司高管Joseph Morrissey为临时首席执行官,董事会主席Carrie Cox为执行主席;公布审计委员会调查结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","OGN","BK4559","LU2065171402.SGD","LU2065170008.USD","LU2065171311.SGD","BK4007","BK4588","BK4585"],"gpt_icon":0},{"id":"1114403675","title":"欧盟委员会批准复宏汉霖和Organon公司的Bildyos®(地诺单抗)和Bilprevda®(地诺单抗)生物类似药,分别为Prolia(地诺单抗)和Xgeva(地诺单抗)的生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1114403675","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114403675?lang=zh_cn&edition=full","pubTime":"2025-09-19 18:01","pubTimestamp":1758276103,"startTime":"0","endTime":"0","summary":"欧盟委员会批准复宏汉霖和Organon公司的Bildyos®(地诺单抗)和Bilprevda®(地诺单抗)生物类似药,分别为Prolia(地诺单抗)和Xgeva(地诺单抗)的生物类似药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4007","LU2065169927.USD","BK4585","LU2065170008.USD","LU2065171402.SGD","02696","BK4559","BK4588","LU2065171311.SGD","OGN"],"gpt_icon":0},{"id":"2568409303","title":"Organon & Co.盘中异动 股价大涨5.02%报10.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568409303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568409303?lang=zh_cn&edition=full","pubTime":"2025-09-18 02:03","pubTimestamp":1758132180,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日02时03分,Organon & Co.股票出现异动,股价快速上涨5.02%。截至发稿,该股报10.88美元/股,成交量212.879万股,换手率0.82%,振幅5.21%。Organon & Co.股票所在的制药行业中,整体涨幅为0.56%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的制药公司,通过女性健康、生物仿制药和知名品牌的处方疗法组合开发和提供健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918020301a4cc129e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918020301a4cc129e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU2065169927.USD","LU2065171402.SGD","BK4585","LU2065170008.USD","BK4559","BK4588","LU2065171311.SGD","OGN"],"gpt_icon":0},{"id":"2564805704","title":"首个“中国籍”地舒单抗在美获批上市!复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2564805704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564805704?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:32","pubTimestamp":1756809132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2065169927.USD","BK1161","BK4585","BK4559","OGN","LU2065171402.SGD","02696","BK4007","LU2065170008.USD","BK4588","LU2065171311.SGD"],"gpt_icon":0},{"id":"1107634666","title":"美国FDA批准复宏汉霖和Organon & Co的Bildyos®(德诺单抗-Nxxp)和Bilprevda®(德诺单抗-Nxxp),分别为Prolia(德诺单抗)和Xgeva(德诺单抗)的生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1107634666","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107634666?lang=zh_cn&edition=full","pubTime":"2025-09-02 17:31","pubTimestamp":1756805487,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)正式批准了复宏汉霖和Organon & Co联合开发的两款生物类似药——Bildyos®(德诺单抗-Nxxp)和Bilprevda®(德诺单抗-Nxxp),这两款药物分别是Prolia(德诺单抗)和Xgeva(德诺单抗)的生物类似药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065171311.SGD","BK4559","BK4588","LU2065170008.USD","OGN","LU2065169927.USD","BK4585","BK4007"],"gpt_icon":0},{"id":"2558968174","title":"Organon & Co.2025财年第二财季实现净利润1.45亿美元,同比减少25.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558968174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558968174?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841679,"startTime":"0","endTime":"0","summary":"8月11日,Organon & Co.公布财报,公告显示公司2025财年第二财季净利润为1.45亿美元,同比减少25.64%;其中营业收入为15.94亿美元,同比减少0.81%,每股基本收益为0.56美元。从资产负债表来看,Organon & Co.总负债127.67亿美元,其中短期债务1.15亿美元,资产负债比为1.06,流动比率为1.66。机构评级:截至2025年8月11日,当前有6家机构对Organon & Co.目标价做出预测,其中目标均价为13.17美元,其中最低目标价为9.00美元,最高目标价为18.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000308a4805721&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000308a4805721&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGN"],"gpt_icon":1},{"id":"2557593656","title":"Organon & Co.盘中异动 下午盘急速上涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557593656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557593656?lang=zh_cn&edition=full","pubTime":"2025-08-08 02:33","pubTimestamp":1754591587,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日02时33分,Organon & Co.股票出现波动,股价大幅拉升5.05%。截至发稿,该股报9.16美元/股,成交量311.697万股,换手率1.20%,振幅5.96%。Organon & Co.股票所在的制药行业中,整体跌幅为5.78%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的制药公司,通过女性健康、生物仿制药和知名品牌的处方疗法组合开发和提供健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808023307a47b81e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808023307a47b81e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4559","LU2065171402.SGD","LU2065171311.SGD","BK4588","OGN","LU2065170008.USD","LU2065169927.USD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.organon.com","stockEarnings":[{"period":"1week","weight":-0.0775},{"period":"1month","weight":0.0951},{"period":"3month","weight":-0.3121},{"period":"6month","weight":-0.2531},{"period":"1year","weight":-0.5352},{"period":"ytd","weight":-0.5214}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Organon & Co.是一家特拉华州公司,成立于2020年3月11日。Organon是一家基于科学的全球制药公司,通过一系列针对女性健康,生物仿制药和知名品牌的处方疗法,开发并提供创新的健康解决方案。他们的使命是成为世界领先的女性保健公司,每天为每个女性提供更好,更健康的服务。他们计划利用自身在生殖健康方面的优势,建立一系列健康解决方案,为从青春期到更年期及以后的妇女提供服务。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.081064},{"month":2,"riseRate":0.5,"avgChangeRate":-0.003366},{"month":3,"riseRate":0.25,"avgChangeRate":-0.00635},{"month":4,"riseRate":0.25,"avgChangeRate":-0.042245},{"month":5,"riseRate":0.5,"avgChangeRate":-0.044845},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004329},{"month":7,"riseRate":0.6,"avgChangeRate":0.002574},{"month":8,"riseRate":0.4,"avgChangeRate":0.012058},{"month":9,"riseRate":0.2,"avgChangeRate":-0.086411},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058949},{"month":11,"riseRate":0.2,"avgChangeRate":-0.091617},{"month":12,"riseRate":0.6,"avgChangeRate":0.051041}],"exchange":"NYSE","name":"Organon & Co","nameEN":"Organon & Co"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Organon & Co(OGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Organon & Co,OGN,Organon & Co股票,Organon & Co股票老虎,Organon & Co股票老虎国际,Organon & Co行情,Organon & Co股票行情,Organon & Co股价,Organon & Co股市,Organon & Co股票价格,Organon & Co股票交易,Organon & Co股票购买,Organon & Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Organon & Co(OGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}